MA57021B1 - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents
Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patientsInfo
- Publication number
- MA57021B1 MA57021B1 MA57021A MA57021A MA57021B1 MA 57021 B1 MA57021 B1 MA 57021B1 MA 57021 A MA57021 A MA 57021A MA 57021 A MA57021 A MA 57021A MA 57021 B1 MA57021 B1 MA 57021B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- antibody
- biomarker
- level
- therapy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un procédé d'identification d'un sujet souffrant d'une leucémie lymphocytaire chronique (llc), d'un lymphome non hodgkinien (lnh), d'un lymphome à petits lymphocytes (lpl) ou d'une leucémie lymphoblastique aiguë (lla) qui est sensible à un traitement avec un anticorps anti-cd19, ledit procédé comprenant : a) la fourniture d'un échantillon de sang obtenu à partir dudit sujet avant le traitement avec ledit anticorps anti-cd19, b) la détermination du taux d'au moins un biomarqueur dans ledit échantillon choisi dans le groupe constitué de : i) le nombre de cellules nk périphériques, et ii) les taux d'expression de cd16 sur les cellules nk périphériques, c) la comparaison du taux dudit au moins un biomarqueur dans ledit échantillon à un niveau de coupure prédéterminé, les taux dudit au moins un biomarqueur égaux ou supérieurs au niveau de coupure prédéterminé étant indicatifs d'un sujet qui bénéficierait d'un traitement avec un anticorps anti-cd19. La présente invention concerne en outre un procédé de sélection d'un patient pour le traitement selon l'invention et l'utilisation d'un anticorps anti-cd19 pour le traitement d'un tel patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (fr) | 2016-05-30 | 2017-05-30 | Procédés de prédiction de bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA57021B1 true MA57021B1 (fr) | 2024-05-31 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45124A MA45124B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
| MA57021A MA57021B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45124A MA45124B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (fr) |
| EP (2) | EP3465214B1 (fr) |
| JP (2) | JP7066639B2 (fr) |
| KR (1) | KR102416144B1 (fr) |
| CN (2) | CN115932265B (fr) |
| AU (1) | AU2017272608B2 (fr) |
| CY (1) | CY1124768T1 (fr) |
| DK (2) | DK3465214T3 (fr) |
| EA (1) | EA201892542A1 (fr) |
| ES (2) | ES2981046T3 (fr) |
| FI (1) | FI3916392T3 (fr) |
| HR (2) | HRP20210938T1 (fr) |
| HU (2) | HUE054860T2 (fr) |
| IL (1) | IL263103B2 (fr) |
| LT (2) | LT3465214T (fr) |
| MA (2) | MA45124B1 (fr) |
| MD (2) | MD3465214T2 (fr) |
| MX (2) | MX388502B (fr) |
| PL (2) | PL3465214T3 (fr) |
| PT (2) | PT3465214T (fr) |
| RS (2) | RS62155B1 (fr) |
| SG (2) | SG10201911958SA (fr) |
| SI (2) | SI3916392T1 (fr) |
| SM (2) | SMT202100291T1 (fr) |
| WO (1) | WO2017207574A1 (fr) |
| ZA (2) | ZA201808647B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (fr) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combinaison d'anticorps anti-cd19 avec un inhibiteur de bcl -2 et utilisations de celle-ci |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114072424A (zh) | 2019-05-03 | 2022-02-18 | 莫佛塞斯公司 | 具有有限数量的nk细胞的患者中的抗cd19疗法 |
| WO2021084062A1 (fr) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Thérapie anti-cd19 en combinaison avec du lénalidomide pour le traitement de la leucémie ou du lymphome |
| TW202131950A (zh) * | 2019-10-31 | 2021-09-01 | 德商莫菲西斯公司 | 依序抗ｃｄ１９療法 |
| EP4168449A1 (fr) * | 2020-06-22 | 2023-04-26 | MorphoSys AG | Polythérapie antitumorale comprenant un anticorps anti-cd19 et des polypeptides bloquant le point de contrôle immunitaire inné sirpa-cd47 |
| AU2021391623A1 (en) * | 2020-12-04 | 2023-06-29 | Incyte Corporation | Anti-cd19 combination therapy |
| WO2026024668A1 (fr) * | 2024-07-22 | 2026-01-29 | Abbott Laboratories | Procédé de détermination d'un volume d'un liquide dans un échantillon |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| WO2005016326A2 (fr) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| PT1853718E (pt) * | 2005-02-15 | 2015-11-12 | Univ Duke | Anticorpos anti-cd19 e usos em oncologia |
| WO2007002223A2 (fr) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Anticorps cd19 et utilisations |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20100167315A1 (en) | 2006-09-13 | 2010-07-01 | Glycode | Method for investigating the response to a treatment with a monoclonal antibody |
| CA2693053C (fr) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Procedes et compositions permettant l'inhibition de cellules d'expression du cd32b |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| CA2753158A1 (fr) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Anticorps humanises qui se fixent au cd19 et leurs utilisations |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011147834A1 (fr) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Anticorps contre cd19 et utilisations associées |
| EP2409993A1 (fr) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré |
| EP2409712A1 (fr) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré |
| SG190254A1 (en) | 2010-11-15 | 2013-06-28 | Medimmune Llc | Combination therapy for b cell lymphomas |
| EP2524929A1 (fr) | 2011-05-17 | 2012-11-21 | Sanofi | Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B |
| CA2841738C (fr) * | 2011-08-16 | 2022-12-06 | Morphosys Ag | Polytherapie avec anticorps anti-cd19 et analogue de purine |
| SG10201606785UA (en) | 2011-08-16 | 2016-10-28 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| EP2791165A4 (fr) * | 2011-12-12 | 2015-08-05 | Pikamab Inc | Prédiction de la sensibilité vis-à-vis d'une thérapie de maintenance par anticorps |
| US20130273032A1 (en) | 2012-03-02 | 2013-10-17 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
| CA2935748A1 (fr) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Anticorps rfb4 humanises anti-cd22 |
| EP3157553A4 (fr) * | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Traitement de la leucémie lymphoïde chronique (llc) |
| US10969391B2 (en) | 2014-07-11 | 2021-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing hematological cancers |
| JP6916741B2 (ja) | 2015-05-26 | 2021-08-11 | モルフォシス・アーゲー | 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 |
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (fr) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combinaison d'anticorps anti-cd19 avec un inhibiteur de bcl -2 et utilisations de celle-ci |
| HUE063119T2 (hu) | 2017-05-31 | 2024-01-28 | Morphosys Ag | Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114072424A (zh) | 2019-05-03 | 2022-02-18 | 莫佛塞斯公司 | 具有有限数量的nk细胞的患者中的抗cd19疗法 |
| LT4051710T (lt) | 2019-10-31 | 2026-03-10 | Incyte Corporation | Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles |
| TW202131950A (zh) | 2019-10-31 | 2021-09-01 | 德商莫菲西斯公司 | 依序抗ｃｄ１９療法 |
| WO2021084062A1 (fr) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Thérapie anti-cd19 en combinaison avec du lénalidomide pour le traitement de la leucémie ou du lymphome |
| EP4168449A1 (fr) | 2020-06-22 | 2023-04-26 | MorphoSys AG | Polythérapie antitumorale comprenant un anticorps anti-cd19 et des polypeptides bloquant le point de contrôle immunitaire inné sirpa-cd47 |
| AU2021391623A1 (en) | 2020-12-04 | 2023-06-29 | Incyte Corporation | Anti-cd19 combination therapy |
| US20230357392A1 (en) | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
-
2017
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/fr not_active Ceased
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/fr active Active
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 CN CN202211271570.5A patent/CN115932265B/zh active Active
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/fr active Active
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US12631639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45124A (fr) | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients | |
| Strasser et al. | Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile | |
| Varettoni et al. | Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms | |
| Zoller et al. | Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study | |
| Riches et al. | Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations | |
| Tembhare et al. | Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000 | |
| Fan et al. | Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation | |
| Mercer et al. | Expression and function of TNF and IL-1 receptors on human regulatory T cells | |
| Galluzzo et al. | IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis | |
| Wei et al. | Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice | |
| Guo et al. | Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients | |
| Coffey et al. | Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory B-cell malignancies | |
| US10725029B2 (en) | Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample | |
| Shinohara et al. | A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction | |
| Worasilchai et al. | Monitoring anti-Pythium insidiosum IgG antibodies and (1→ 3)-β-d-glucan in vascular pythiosis | |
| Chihara et al. | Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan | |
| Hannula-Jouppi et al. | Genetic susceptibility to non-necrotizing erysipelas/cellulitis | |
| Angelot‐Delettre et al. | Intracytoplasmic detection of TCL1—but not ILT7—by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis | |
| Mitrovic et al. | CD 43 expression is associated with inferior survival in the non‐germinal centre B‐cell subgroup of diffuse large B‐cell lymphoma | |
| Wang et al. | Transcriptome analysis of gingival tissues of enamel‐renal syndrome | |
| Isidro-Hernández et al. | Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice | |
| Nishi et al. | FilGAP, a Rac‐specific Rho GTPase‐activating protein, is a novel prognostic factor for follicular lymphoma | |
| Ilhan et al. | Leukemic stem cells shall be searched in the bone marrow before “tyrosine kinase inhibitor‐discontinuation” in chronic myeloid leukemia | |
| Dehmel et al. | Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long‐term renal allograft outcome | |
| Hartling et al. | Gene variation in IL-7 receptor (IL-7R) α affects IL-7R response in CD4+ T cells in HIV-infected individuals |